Exceptional Response to Nanoparticle Albumin-Bound Paclitaxel and Gemcitabine in a Patient with a Refractory Adenocarcinoma of the Ampulla of Vater

Publisher： Karger

E-ISSN： 1662-6575|9|1|15-24

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.9, Iss.1, 2016-01, pp. : 15-24

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL®®-free formulation of paclitaxel

By Stinchcombe Thomas E  

Nanomedicine, Vol. 2, Iss. 4, 2007-08 ,pp. : 415-423

Future Medicine

Access to resources Recommend Favorite

Toxic erythema with eccrine squamous syringometaplasia induced by nanoparticle albumin‐bound paclitaxel

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 11, 2015-11 ,pp. : 1134-1135

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nanoparticle albumin‐bound paclitaxel can be useful agent to advanced primary mucinous carcinoma of the skin

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 11, 2015-11 ,pp. : 2271-2273

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

By  

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1817-1826

John Wiley & Sons Inc

Access to resources Recommend Favorite

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin‐bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 7, 2015-07 ,pp. : 1214-1221

John Wiley & Sons Inc

Access to resources Recommend Favorite